Decades of clinical evidence and the consensus of the world’s leading medical organizations are currently colliding with a new wave of legislative efforts in the U.S. Congress. At the center of this friction is mifepristone, the medication used in roughly two-thirds of U.S. Abortions, which is now the subject of investigations and proposed bans based on data that health experts describe as misleading.
The push to revoke the drug’s Food and Drug Administration (FDA) approval is being led by Senator Josh Hawley, who has pointed to a report from the faith-centric Ethics and Public Policy Center (EPPC). The report claims a rate of adverse events significantly higher than what is supported by established research. However, the findings have been widely criticized by the medical community for contradicting extensive FDA review data and the safety assessments of the American Medical Association (AMA) and the World Health Organization (WHO).
As a physician, I have seen how the translation of research into public policy can be distorted when clinical data is bypassed in favor of ideological reports. The current tension over the abortion pill’s safety is not an isolated incident; it is part of a broader, systemic shift in how health misinformation is managed, moderated, and utilized to shape federal and state law.
This environment is further complicated by a shifting legal landscape regarding free speech and censorship. From the settlement of federal lawsuits over COVID-19 content moderation to Supreme Court rulings on medical practice restrictions, the boundary between regulating harmful medical misinformation and protecting viewpoint discrimination is becoming increasingly blurred.
The Gap Between Clinical Data and Legislative Action
The effort to challenge the safety of mifepristone is manifesting in both legislative probes and state-level litigation. Senator Hawley has not only proposed legislation to revoke the drug’s FDA approval but has also launched an investigation into the companies that manufacture and distribute the pill, alleging they ignored critical safety information.
Medical professionals argue that these claims ignore a vast body of evidence. The American College of Obstetricians and Gynecologists (ACOG) and other major bodies have reaffirmed the drug’s long-term safety record. Despite this, the narrative of “unsafe” medication is gaining traction. According to a November 2025 KFF Health Tracking Poll, public confidence in the drug’s safety has declined, falling from 55% in 2023 to 42% in 2025.
This erosion of trust coincides with state-level lawsuits led by Florida, Louisiana, and Missouri. These legal challenges target the FDA’s original approval and the subsequent modifications that allow the drug to be dispensed via mail—a critical access point for patients in states where abortion is banned and who are increasingly relying on telehealth.
Comparative Perspectives on Mifepristone Safety
| Source | Finding/Position | Basis of Claim |
|---|---|---|
| FDA, WHO, AMA, ACOG | Safe and effective | Decades of clinical trials and post-market surveillance |
| EPPC Report | Higher rate of adverse events | Faith-centric policy analysis |
| Sen. Josh Hawley | Calls for FDA revocation | Citing the EPPC report |
The Legal Battle Over Health Misinformation
Whereas the debate over mifepristone continues, a parallel struggle is occurring over who has the right to flag health misinformation online. The Trump administration recently settled a high-profile lawsuit alleging that federal officials violated the First Amendment by pressuring social media companies to remove false COVID-19 content. Under the settlement, the CDC, the Surgeon General’s office, and CISA are now prohibited from threatening social media companies with regulatory penalties to compel content removal.
This settlement frames a victory for “free speech” for some, but for public health officials, it represents a loss of a critical tool for combating viral falsehoods. This tension is mirrored in a new lawsuit filed by a coalition of academic researchers. They argue that the administration is engaging in its own form of censorship by excluding or deporting noncitizens whose professional work involves fact-checking and combating misinformation.
The Supreme Court has also entered this fray with a ruling on “conversion therapy.” The court found that a Colorado law prohibiting therapists from promoting these practices to minors may have violated the First Amendment by restricting speech based on viewpoint. Major medical organizations warn that this ruling could lead to the wider adoption of practices they have identified as ineffective and linked to increased rates of depression and suicidality.
The Rise of Unproven Treatments and AI Reliance
The vulnerability of the public to unproven health claims is further evidenced by the growing popularity of peptides. These injectable substances are marketed in wellness communities for anti-aging and muscle recovery, often through a “gray market” labeled for research use only. Despite a lack of robust clinical evidence, Google searches for these substances reached 10.1 million in January, with anti-aging searches up nearly 300% year-over-year.
In a move that surprised career scientists, the FDA is reportedly planning to lift restrictions on roughly 14 peptides that were removed from compounding pharmacy lists in 2023 due to safety risks. HHS Secretary Robert F. Kennedy Jr., a vocal supporter of these treatments, argues that licensed pharmacies provide better safety standards than the gray market. However, critics worry that basing regulatory decisions on the personal beliefs of officials rather than clinical trials undermines the agency’s scientific integrity.
Compounding this is a growing reliance on Artificial Intelligence for medical advice. A March 2026 KFF poll found that 32% of the public has used AI for health information in the past year. While speed is the primary driver, 19% of users cited the inability to afford a healthcare provider as a major reason for turning to AI. This trend is most pronounced among those under 30 and those earning below $40,000, creating a dangerous gap where the most financially vulnerable patients may act on unreliable AI-generated advice without clinical follow-up.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The intersection of political action, legal rulings on speech, and the deregulation of medical substances suggests a period of instability for public health standards. The next critical checkpoint will be the progression of the federal lawsuits regarding misinformation researchers and the potential legislative votes on the revocation of mifepristone’s FDA approval.
We invite you to share your thoughts on the balance between free speech and medical regulation in the comments below.
